Catalent signs deal with Moderna to speed up U.S. vaccine output

URLhttps://www.reuters.com/article/us-health-coronavi
SourceReuters
Date Published04/06/2021
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Catalent, Inc.
Type of work Manufacturing
If manufacturing, is the company a contract manufacturer?Yes
Reshoring category:Reshoring
Year reshoring announced:2021
Year reshoring implemented or to be implemented:2021
Domestically, the work will be done:In-house
City reshored to:Bloomington
State(s) reshored to:IN
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredvials of Moderna’s COVID-19 vaccine
What domestic positive factors made reshoring more attractive?Skilled workforce availability/training, Under-utilized capacity, Other, Covid-19, import replacement
Find Reshoring Articles